Table of Contents Table of Contents
Previous Page  741 / 812 Next Page
Information
Show Menu
Previous Page 741 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S737

He has always chosen male activities and male stereotypes compa-

nies. He has presented preference for cross-dressing from 9 years.

Always felt the sexual attraction for women. He first consulted for

this reason in 1995.

Results

It reported favorably to start hormone treatment after

completing the eligibility criteria: > 18 years old; knowledge of the

effects of hormones; and more 3 months documented real-life

experience. The hormone therapy caused the growth of micro-

prolactinoma, which was treated with dopamine agonists until it

disappeared and the cessation of galactorrhea. Testosterone treat-

ment is restarted. Laboratory tests are done every 3 months during

the first year and then, every 6 months.

Conclusions

Is the gender disphoria a pathology? The EU recom-

mends a reclassification as no pathological disorders in ICD-11. The

treatment of gender dysphoria is necessary, and there is no rea-

son to postpone it. The main difficulty is the differential diagnosis;

there may be comorbidity with others mental disorders which are

not exclusive (psychotic disorder, OCD, personality disorders and

other disorders of gender identity).

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2199

EV1215

Primary and secondary

transsexualism, really?

F. Jurysta

1 , 2 ,

, G. Hladki

2

1

Centres Hospitaliers Jolimont Asbl, Psychiatrie, Haine-Saint-Paul,

Belgium

2

ULB, Hôpital Erasme, Centre de Sexologie et des Troubles de

l’Identité du Genre CESTIG, Brussels, Belgium

Corresponding author.

Introduction

Transsexualismsuffers fromseveral definitions that

evolve across time. Therefore, some discrepancies appear progres-

sively in regard of evidence-based medicine and psychological

approaches as sexo-analysis.

Objectives

In our present study, we test if “primary” or “sec-

ondary” transsexualism defines in accordance with sexo-analysis

definitions will be reliable with the pathology course.

Aims

Clarify the definition of transsexualism to obtain a better

understanding of this trouble and perhaps to change psychological

approaches of gender disorders.

Methods

Nine transsexual male-to-female (MtF) aged between

25 to 65 were voluntary recruited. They were diagnosed by a

psychiatrist. We adapted the GID scale to measure the lifetime pro-

cess. Descriptive statistics were reported. Results are expressed as

mean

±

standard deviation.

Results

Age of the group is 41

±

12. All subjects were treated by

hormone therapy. One of themwas surgical reassigned. All subjects

reported a persistent feeling to be a woman across their entire life.

None showed a decreased female feeling during a part of their life

or a brutal apparition of this trouble during the adult period.

Conclusions

In regards of our preliminary results, we concluded

that secondary transsexualism should be redefined and was prob-

ably induced by sociocultural aspects. Our results are limited by

amount of subjects and should be confirmed by a large population

included MtF and FtM people.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2200

EV1216

Sex, drugs and enhanced libido

B. Macías

, N. Serrano , M. Díaz

Hospital Dr. Rodríguez Lafora, Psiquiatría, Madrid, Spain

Corresponding author.

Introduction

Twenty-eight years old male, admitted into a long-

stay unit diagnosed of schizoaffective disorder, who has presented

behavioural disturbances consisted in sexual disinhibition.

Case report

Since the patient was 15 years old, he has pre-

sented several behavioural disturbances and erotomanic and

reference delusions, which have not ended even after begin-

ning treatment with clozapine. Nowadays treatment consists

of clozapine 600mg/day, haloperidol 20mg/day, amisulpiride

2000mg/day, olanzapine 30mg/day, ciproterone 50mg/day, val-

proic acid 2300mg/day, clorazepate dipotassium 15mg/day,

lorazepam 7.5mg/day, nevertheless the patient still presents

sexual disinhibition against other patients and staff members

(masturbation, exhibitionism, frotteurism, coprolalia). During

treatment, he has suffered from hyperprolactinaemia, but this

entity did not decrease the patient’s sexual desire.

Discussion

Although this patient has been treated with a wide

pharmacologic strategy, it has not been effective, so it should be

highlighted how a mixed approach including also psychotherapy,

could be more useful in controlling the libido.

Conclusions

This case is an example of variability among patients

and how antipsychotic drugs and chemical castration are not

always useful for decreasing enhanced sex drive.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2201

EV1217

Secondary sexual dysfunction with

antidepressant treatment: Study on 50

patients

O.W. Muquebil Ali Al Shaban Rodriguez

1 ,

, S. Ocio León

1

,

M. Gómez Simón

2

, M.J. Hernández González

1

,

E. Álvarez de Morales Gómez-Moreno

3

, C. Huergo Lora

4

,

J.R. López Fernández

4 , A. G

onzález Suárez

4 ,

A. Barrio Nespereira

5 , G.

Gutiérrez Vázquez

6 , L. T

u˜nón Gorgojo

7

1

Centro de Salud Mental Mieres, Psychiatry, Mieres del Camino,

Spain

2

Centro de Salud Mental Mieres, Psychology, Mieres del Camino,

Spain

3

CSM Puerta de la Villa, Psichiatry, Gijón, Spain

4

Hospital Vital Álvarez-Buylla, Psichiatry, Mieres del Camino, Spain

5

CSM Puerta de la Villa, Psycology, Gijón, Spain

6

CSM El Quirinal, Psichiatry, Avilés, Spain

7

Centro de Salud Mieres Sur, Nursing, Mieres del Camino, Spain

Corresponding author.

Introduction

The side effects of the various antidepressant drugs

on the sexual field (with very few exceptions) are well known, and

they affect the quality of life in important manners. The incidence

rate, communicated spontaneously by the patient, has been esti-

mated around 10–15%, and can reach amounts of 50–60%with SSRIs

when studied specifically. It has been suggested that these effects

compromise treatment adherence.

Objectives

To estimate the incidence and intensity of the side

effects on the sexual field with different antidepressants, as well

as its relationship with treatment adherence.

Methodology

Transversal study on 50 patients assisted in medi-

cal consultation. Collection of data in office (October 2014–October

2015).

Administration of survey PRSexDQ-SALSEX. In order to research the

relationship with treatment adherence, one question surveyed the

patient whether he/she had thought about finishing treatment for

this reason.

Results

Twenty-nine patients (58% of the sample) presented

some degree of sexual dysfunction. Five individuals (17.2%) com-

municated it spontaneously. Nine individuals (31%) responded that

they did not accept positively the changes in their sexual field, and

they had thought about withdrawing treatment for this reason.